Gastrointestinal Cancer

Gastrointestinal Cancer

Disease-Specific Survival of AJCC 8th Stage II Gastric Cancer Patients After D2 Gastrectomy

The purpose of this study is to investigate the independent risk factors for treatment failure in stage II gastric cancer.

Frontiers in Oncology
KIT Inhibitor Combination Shows Efficacy in Refractory GIST

Investigators find that the combination of a type I KIT inhibitor, PLX9486, with the type II inhibitor sunitinib produces clinical benefit and improves PFS rates in patients with GIST.

The ASCO Post
Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

In May 2021, nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or GEJ cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.

The ASCO Post

Identification and Validation of the Immune Regulator CXCR4 as a Novel Promising Target for Gastric Cancer

This study has determined the prognostic value of 11 immunomodulatory factors in gastric cancer.

Frontiers in Immunology
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors

This study seeks to answer the question: Is cotargeting the active and inactive conformations of KIT associated with clinical benefit in refractory GIST?

JAMA Oncology
Aberrant Non-Coding RNA Expressed in Gastric Cancer and Its Diagnostic Value

Study investigators measure miRNA, lncRNA and cirRNA expression profiles of gastric cancer patients by using microarray and RNA-sequencing data from tissue samples.

Frontiers in Oncology
Addition of Neoadjuvant Chemotherapy to Surgery and Adjuvant S-1 in Locally Advanced Gastric Cancer

Dr Kang and colleagues find the addition of neoadjuvant docetaxel, oxaliplatin, and S-1 to D2 gastrectomy followed by adjuvant S-1 is associated with improved PFS in patients...

The ASCO Post
Addition of First-Line Nivolumab to Chemotherapy in Advanced Gastric Cancers

The phase III CheckMate 649 trial shows that the addition of first-line nivolumab to CT results in improved overall and PFS among patients with advanced HER2- gastric, GEJ, and...

The ASCO Post
PET Response–Adapted Chemoradiotherapy for Esophageal and Esophagogastric Junction Adenocarcinoma

Mature results of the phase II CALGB 80803/Alliance trial indicate that treatment guided by early PET assessment of response to induction neoadjuvant CT improves pathologic complete response rates

The ASCO Post
Novel Prognostic Biomarkers in Gastric Cancer: CGB5, MKNK2, and PAPPA2

The present study uses bioinformatics to identify prognostic markers for gastric cancer that would guide the clinical diagnosis and treatment of this disease.

Frontiers in Oncology
Adjuvant Imatinib Therapy Offers Survival Benefit in Patients With Resected GIST, but Team Effort May Be Needed to Reduce Early Discontinuation Rates

Clinical trial data show that adjuvant imatinib improves RFS as well as OS, when administered for at least 3 years, among patients who undergo a macroscopically complete resection of a primary GIST

The ASCO Post
Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer

The trial evaluated first-line treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab in patients with advanced disease.

The ASCO Post
A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy

The aims of this study are to develop and validate a novel nomogram to predict thromboembolism in gastric cancer patients receiving chemotherapy and to test its predictive ability.

Frontiers in Oncology
Surprising Percentage of Biopsy Samples Found Retained in GI Endoscopes

Researchers examining GI endoscopes after colonoscopy and EGD procedures found a "startlingly high" rate of retained biopsy samples in the endoscope accessory channel or cap.

Radiotherapy Effective for H Pylori–Independent Gastric MALT

Radiation therapy alone was highly effective for the treatment of Helicobacter pylori–independent GML, according to the results of a single-center retrospective study.

Cancer Therapy Advisor
Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma

This study analyzes variations in plasma cell-free DNA amount to search for minimal residual disease.

Frontiers in Oncology
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2

This investigator-initiated, single-arm phase II study assesses the role of the PARPi rucaparib as maintenance therapy in advanced PC with germline or somatic PV in BRCA1, BRCA2, or PALB2.

Journal of Clinical Oncology
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors

Study investigators examine the efficacy and safety of lenvatinib in patients with previously treated advanced gastroenteropancreatic neuroendocrine tumors.

Journal of Clinical Oncology
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

This study aims to answer the question do older and/or frail patients with advanced gastroesophageal cancer benefit from less intensive palliative CT, and can a formal geriatric assessment assist..

JAMA Oncology
Esophageal Cancer: Preop Chemoradiotherapy Benefit for 10 Years

Among patients with locally advanced resectable esophageal or junctional cancer, the overall survival benefit conferred by preoperative chemoradiotherapy persists for at least 10 years.

Hepatic Metastasis in Newly Diagnosed Esophageal Cancer

The primary objective of this study is to explore the predictors of esophageal cancer with hepatic metastasis at the time of diagnosis. 

Frontiers in Oncology
Retrieval of 30 Lymph Nodes Is Mandatory for Selected Stage II Gastric Cancer Patients

This study aims to explore the impact of retrieving 30 or more lymph nodes on the survival of stage II cancer patients.

Frontiers in Oncology
Ten-Year Outcomes With Neoadjuvant Chemoradiotherapy Plus Surgery vs Surgery Alone for Esophageal Cancer

This 10-year follow-up of the Dutch CROSS trial shows a continued OS benefit with neoadjuvant chemoradiotherapy plus surgery vs surgery alone in patients with locally advanced resectable esophageal

The ASCO Post
Adjuvant Nivolumab Practice-Changing in Resected Gastroesophageal Cancer

A “significant and clinically meaningful” improvement of disease-free survival is observed in a Phase III trial among patients who already had their esophageal or gastroesophageal cancers treated w

Oncology Times - Latest Articles
Andecaliximab Disappoints in Advanced Gastric Cancer

Adding andecaliximab to first-line treatment with modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) provides no survival benefit in patients with advanced HER2-negative gastric...

Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer

The UNICANCER-PRODIGE 23 trial has shown intensification of preoperative therapy with FOLFIRINOX prior to chemoradiotherapy results in improved disease-free survival in...

The ASCO Post
FDA Grants Breakthrough Therapy Designation to Bemarituzumab for Gastric Cancers

The FDA grants breakthrough therapy designation to bemarituzumab for use with CT as first-line treatment of certain patients with GI cancers, according to the agent’s manufacturer.

Anesthesiologist Volume and Adverse Short-Term Outcomes After Complex Surgery for Gastrointestinal Cancer

Hallet et al find that higher anesthesiologist volume is associated with reduced risk of short-term adverse postoperative outcomes in patients undergoing complex surgery for gastrointestinal cancer

The ASCO Post
Zolbetuximab Plus EOX Versus EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma

This phase II study evaluates clinical outcomes of zolbetuximab + EOX versus EOX alone in advanced CLDN18.2+ gastric cancer.

Annals of Oncology
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer

The multicenter VARIANZ study aims to investigate the background of response and resistance to trastuzumab in mGC.

Journal of Clinical Oncology
Exploring the Attitudes of Health Professionals Providing Care to Patients Undergoing Treatment for Upper Gastrointestinal Cancers to Different Models of Nutrition Care Delivery

This study aims to explore the perspectives of health professionals on providing nutrition care to upper gastrointestinal cancer patients by electronic methods to allow the future scaling-up of acc

MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors

The aim of this review is to summarize the major studies that have investigated the role of microRNAs as mediators of resistance to targeted therapies currently in use in GI neoplasms...

Effects of Cooperative Nursing and Patient Education on Postoperative Infection and Self-Efficacy in Gastrointestinal Tumors

This study aims to explore the effect of cooperative nursing care management/self-efficacy education on postoperative infection and self-efficacy in gastrointestinal tumor surgery patients.

World Journal of Clinical Cases

source list reference